Umbilical Cord Mesenchymal Cellules souches Therapy for Diabetic Nephropathy
Bref résumé:
This clinical trial assessed the safety of human umbilical cord mesenchymal thérapie par cellules souches dans 15 patients with diabetic nephropathy. Fifteen subjects received umbilical cord mesenchymal thérapie par cellules souches 3 times. Approximately 1 × 106/kg of human umbilical cord mesenchymal stem cells were administered by peripheral intravenous infusion once a month .Endpoints:Primary endpoint: Safety and adverse events (safety and tolerability of umbilical cord mesenchymal thérapie par cellules souches within 60 semaines).Secondary endpoint indicators:Efficacy measures: eGFR, urinary albumin-to-creatinine ratio, and percentage changes of 24-h urinary protein quantities from baseline to 60 semaines.
